Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study

• Published in: European journal of internal medicine Vol. 84; pp. 63 - 67
• Main Authors: Della-Torre, Emanuel, Lanzillotta, Marco, Campochiaro, Corrado, Di-Colo, Giulia, Mancuso, Gaia, Capurso, Gabriele, Falconi, Massimo, Dagna, Lorenzo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2021
• Subjects: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; B-cells; biosimilar; Biosimilar Pharmaceuticals; Cohort Studies; Humans; IgG4; IgG4-related disease; Immunoglobulin G4-Related Disease; Prospective Studies; Rituximab; therapy; Treatment Outcome; B-cells; IgG4; IgG4-related disease; therapy; rituximab; biosimilar

•High costs limit rituximab wide off-label administration in IgG4-related disease•Biosimilars are used in alternative to originators in many autoimmune disorders•Rituximab biosimilar CT-P10 is safe and effective in IgG4-related disease•This study first reports on a rituximab biosimilar in IgG4-relat...